Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Transfus Apher Sci ; 54(1): 2-15, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26776481

ABSTRACT

Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a multinational registry. The WAA-apheresis registry data focus on adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs were graded as mild, moderate (need for medication), severe (interruption due to the AE) or death (due to AE). More AEs occurred during the first procedures versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea 3%), and severe in 0.4% of procedures (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/asystole 4.5%, nausea/vomiting 4%). Hypotension was most common if albumin was used as the replacement fluid, and urticaria when plasma was used. Arrhythmia occurred to similar extents when using plasma or albumin as replacement. In 64% of procedures with bronchospasm, plasma was part of the replacement fluid used. Severe AEs are rare. Although most reactions are mild and moderate, several side effects may be critical for the patient. We present side effects in relation to the procedures and suggest that safety is increased by regular vital sign measurements, cardiac monitoring and by having emergency equipment nearby.


Subject(s)
Blood Component Removal/adverse effects , Registries , Societies, Medical , Adolescent , Adult , Aged , Aged, 80 and over , Calcium/administration & dosage , Child , Child, Preschool , Colloids , Female , Humans , Infant , Infant, Newborn , Injections, Intravenous , Male , Middle Aged , Plasma Exchange , Reference Standards , Time Factors , Tissue Donors , Treatment Outcome , Young Adult
3.
Int Angiol ; 31(1): 77-84, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22330628

ABSTRACT

AIM: Trials have reported clinical improvement and reduced need for amputation in critical limb ischemia (CLI) patients receiving therapeutic angiogenesis with stem cells. Our objective was to test peripheral stem cell therapy efficacy and safety to gain experiences for further work. METHODS: We included nine CLI patients (mean age 76.7 ±9.7). Stem cells were mobilized to the peripheral blood by administration of G-CSF (Filgrastim) for 4 days, and were collected on day five, when 30 mL of a stem cell suspension was injected into 40 points of the limb. The clinical efficacy was evaluated by assessing pain relief, wound healing and changes in ankle-brachial pressure index (ABI). Local metabolic and inflammatory changes were measured with microdialysis, growth factors and cytokine level determination. Patients were followed for 24 weeks. RESULTS: Four patients experienced some degree of improvement with pain relief and/or improved wound healing and ABI increase. One patient was lost to follow up due to chronic psychiatric illness; one was amputated after two weeks. Two patients had a myocardial infarction (MI), one died. One patient died from a massive mesenteric thrombosis after two weeks and one died from heart failure at week 11. Improved patients showed variable effects in cytokine-, growth factor- and local metabolic response. CONCLUSION: Even with some improvement in four patients, severe complications in four out of nine patients, and two in relation to the bone marrow stimulation, made us terminate the study prematurely. We conclude that with the increased risk and the reduced potential of the treatment, peripheral blood stem cell treatment in the older age group is less appropriate. Metabolic and inflammatory response may be of value to gain insight into mechanisms and possibly to evaluate effects of therapeutic angiogenesis.


Subject(s)
Ischemia/surgery , Lower Extremity/blood supply , Peripheral Blood Stem Cell Transplantation/adverse effects , Aged , Aged, 80 and over , Amputation, Surgical , Angiography, Digital Subtraction , Ankle Brachial Index , Critical Illness , Cytokines/blood , Drug Administration Schedule , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/administration & dosage , Heart Failure/etiology , Heart Failure/mortality , Hematopoietic Stem Cell Mobilization , Humans , Intercellular Signaling Peptides and Proteins/blood , Ischemia/blood , Ischemia/complications , Ischemia/diagnosis , Ischemia/mortality , Ischemia/physiopathology , Limb Salvage , Male , Mesenteric Vascular Occlusion/etiology , Mesenteric Vascular Occlusion/mortality , Middle Aged , Myocardial Infarction/etiology , Pain/etiology , Pain/prevention & control , Pain Measurement , Peripheral Blood Stem Cell Transplantation/mortality , Pilot Projects , Predictive Value of Tests , Recombinant Proteins/administration & dosage , Reoperation , Risk Assessment , Risk Factors , Sweden , Thrombosis/etiology , Thrombosis/mortality , Time Factors , Transplantation, Autologous , Treatment Outcome , Wound Healing
4.
Transfus Apher Sci ; 45(2): 119-23, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21885345

ABSTRACT

Thrombotic microangiopathy (TMA) is a histopathological feature of various diseases including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). There are many secondary causes of TMA, many of them could mimic TTP or HUS. This article presents a short overview on TMA. In conclusion TMA is the result of various etiology reasons and pathologic reactions with various clinical entities. It is important to focus on a thorough history including family history when deciding on a diagnosis. Analysis of ADAMTS 13 and ADAMTS 13-antibodies may help to decide continued therapy.


Subject(s)
Thrombotic Microangiopathies/pathology , Female , Hemolytic-Uremic Syndrome/pathology , Humans , Male , Purpura, Thrombotic Thrombocytopenic/pathology
5.
Transfus Apher Sci ; 45(2): 125-31, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21903476

ABSTRACT

UNLABELLED: Thrombotic Microangiopathy (TMA) is a histopathological feature of various diseases including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The aim of this study was to investigate the outcome and prognostic variables of TMA-patients. MATERIALS AND METHODS: Data were consecutively retrieved from the WAA-apheresis registry (www.waa-registry.org) during 2003-2009. Included were all 120 patients (1237 procedures) who suffered from various forms of TMA, as registered by the ICD-10 code M31.1. Besides registry data, more extensive information was retrieved from the latest 64 patients. Adverse events of the TMA patients were compared to those of the other patients in the registry. RESULTS: The mean age was 46 years (range 11-85 years, 57% women). In 72% therapeutic apheresis was due to an acute indication while a long-term indication was present in 28%. Plasma exchange was performed by centrifugation and filtration technique (95% and 4%, respectively), and immunoadsorption in 1% of the patients. Only fresh frozen plasma was used as replacement fluid in 69% of procedures. Adverse events were more frequent than in the general apheresis population (10% versus 5%, RR 1.9, CI 1.6-2.3). No death occurred due to apheresis treatment. Three percent of the procedures were interrupted. Bronchospasm and/or anaphylactic shock were present in two patients and one patient suffered from TRALI. At admission 26% were bedridden and needed to be fed. The risk of dying during the treatment period was significantly higher if the patient also suffered from a compromising disease, such as cancer. There was an inverse correlation between the ADAMTS13 level and the antibody titer (r=-0.47, p=0.034). CONCLUSIONS: Patients with TMA have an increased risk for moderate and severe AE compared to the general apheresis population. Many patients were severely ill at admission. The prognosis is worse if the patient also has a severe chronic disease. Even slightly increased ADAMTS13-antibody titers seem to have a negative impact on the ADAMTS13 levels.


Subject(s)
Hemolytic-Uremic Syndrome/diagnosis , Hemolytic-Uremic Syndrome/therapy , Purpura, Thrombotic Thrombocytopenic/diagnosis , Purpura, Thrombotic Thrombocytopenic/therapy , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Blood Component Removal/adverse effects , Child , Female , Humans , Male , Middle Aged , Prognosis , Registries , Statistics as Topic/methods , Young Adult
6.
Transfus Apher Sci ; 39(3): 255-60, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19010084

ABSTRACT

OBJECTIVES: Paediatric patients are a special group in apheresis. It is general accepted to use adult indications in paediatric patients, but data in this age group are rare. In order to provide more information of apheresis practise in children and young adults (<21a) we will report of knowledge learnt by data from the registry from 2003 until 2007. METHODS: This is a web-based registry. A link is available from the WAA homepage (www.worldapheresis.org). So far data from 12,448 procedures have been included. Six hundred and twelve procedures were performed in 135 children and young adults (308 procedures<16a, 237 from 17 to 20a, and 67 with 21a) representing 5% of the total population. The median age was 14 years (range 1-21 years), 74 male and 61 female. These data were entered by 15 centres with a frequency of in median 18 aphereses in young patients per centre (range 1-287) from 2003 to 2007. RESULTS: Main indications: haematological diseases and also nephrological, and neurological. The type of aphereses was mainly Leukapheresis (196, 33%), plasma exchange (149, 25%), photopheresis (127, 21%), and lipid aphereses (79, 13%). Blood access: peripheral vessels in 305 procedures (50%, compared to 73% in adults), central venous catheter in 239 (38%), and AV-fistula in 2% and 0.3%, and in 8 (1.31%) procedures an arterial line was used. Anticoagulation was mostly by ACD (71%), heparin (18% or the combination of both (3%). 39 adverse events (AE) were registered in 22 (=3.59%) of the procedures, mostly graded as mild. Treatment was interrupted in 14 procedures (2.29%). AE's were abdominal pain, anaphylactic shock, flush, hyper- and hypotension, nausea, vertigo, cephalea and need for sedation and technical problems with the device and problems with the venous access. The rate of AE's was similar for stem cell harvesting and for plasma exchange (4% and 4.7%, respectively). CONCLUSION: The paediatric data compared to the whole registry data set are showing that aphereses are performed as safe in paediatrics as in adults. Centres are mostly handling only a few cases younger than 21. Therefore more exchange of information and experience in paediatric apheresis is warranted.


Subject(s)
Blood Component Removal , Databases, Factual , Internet , Registries , Adolescent , Adult , Child , Child, Preschool , Female , Hematologic Diseases/therapy , Humans , Infant , Male
7.
Transfus Apher Sci ; 39(3): 247-54, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18977177

ABSTRACT

OBJECTIVES: Seventy-five centers from many countries have applied for a login code to the WAA apheresis registry. Fifteen centers from 7 countries have been actively entering data at the internet site from 2003 until 2007. We report on data from the registry so far. METHODS: This is a web-based registry. A link is available from the WAA homepage (www.worldapheresis.org). So far data from 2013 patients (12,448 procedures) have been included. A median of 6 treatments have been performed (range 1-140). Mean age 51 years (range 1-94 years; 45% women). Seven percent of the patients were < or = 21 years and 4% were < or = 16 years. RESULTS: The purpose of the apheresis procedure was therapeutic in 67% and retrieval of blood components in 33%. Main indications: neurological and hematological diseases, lipid apheresis and stemcell collection (autologous, and some allogeneic). Blood access: peripheral vessels (71%), central dialysis catheter through jugular (6.5%) or subclavian veins (6.7%), femoral vein (8%) and AV fistula (4%). ACD was used for anticoagulation in 73% of the procedures. Albumin was mainly used as replacement fluid. Adverse events (AE) were registered in 5.7% of the procedures. AE was graded as mild (2.5%), moderate (2.7%) or severe (0.5%). No death occurred due to treatment. The procedures were interrupted in 2.6%. Most frequent AEs were blood access problems (29%), tingling around the mouth (20%), hypotension (18%), and urticaria (9%). There were significant differences between the centers regarding mild and moderate AEs. Data indicate that centers using continuous infusion of calcium had fewer AEs. CONCLUSION: There was a limited number of severe AEs. Centers use various standard procedures for apheresis. By learning from the experience of others the treatment quality will improve further. In the near future, an update of the registry will enable more extensive evaluation of the data.


Subject(s)
Blood Component Removal , Databases, Factual , Internet , Registries , Female , Humans , Male
10.
Biochim Biophys Acta ; 533(1): 34-42, 1978 Mar 28.
Article in English | MEDLINE | ID: mdl-25088

ABSTRACT

The non-polar surface properties of beta-lactoglobulin and especially its interaction with poly(ethylene glycol)-bound palmitate has been studied as a function of pH, temperature and protein concentration. The maximum interaction between beta-lactoglobulin and polymer-bound palmitate occurs at pH 4.3 and pH 7.8. The change in conformation of beta-lactoglobulin around pH 7.5 seems to involve exposure of apolar amino acids to the solvent which results in an increased affinity for hydrocarbons. This is contrary to the situation at pH 4.8--6.0 where the corresponding change in conformation does not affect the protein-hydrocarbon interaction. The results suggest that partition studies in an aqueous two-phase system is a very useful tool to detect changes in conformation and aggregation and to characterize the corresponding hydrophobic surface properties of a protein.


Subject(s)
Lactoglobulins , Animals , Cattle , Hydrogen-Ion Concentration , Ligands , Palmitates , Protein Conformation , Solubility , Surface Properties , Temperature
11.
Eur J Biochem ; 71(2): 419-23, 1976 Dec 11.
Article in English | MEDLINE | ID: mdl-1009961

ABSTRACT

The hydrophobic properties of histones have been examined with help of the two-phase partition technique using dextran-poly(ethylene glycol)-water systems. We have found that different fatty acid esters of poly(ethylene glycol) interact with total histones in a manner similar to proteins of the type beta-lactoglobulin and serum albumins. Thus the maximum interaction occurs when the fatty acid contains 16-18 carbon atoms. With less than eight carbon atoms in the polymer-bound fatty acid, no histone-hydrocarbon interaction is observed. The interaction of the five individual histone fractions with palmitate depends on the type of salt used and on its concentration. We suggest that the histones can be divided into three groups with decreasing hydrophobic properties: H3, H2a greater than H4, H2b greater than H1.


Subject(s)
Histones , Hydrocarbons , Histones/analysis , Hydrocarbons/analysis , Kinetics , Molecular Conformation , Osmolar Concentration , Palmitic Acids , Polyethylene Glycols/analysis , Sodium Chloride/pharmacology , Water
12.
Eur J Biochem ; 60(1): 17-22, 1975 Dec 01.
Article in English | MEDLINE | ID: mdl-1263

ABSTRACT

In this report we describe a new method which is useful for measuring hydrophobic interactions between aliphatic hydrocarbon chains and proteins in aqueous environment. The method is based on partition of proteins in an aqueous two-phase system containing dextran and poly(ethylene glycol) and different fatty acid esters of poly(ethylene glycol). The partition is measured under conditions where contributions from electrostatic interactions are eliminated. The difference in partition of proteins in phase systems with and without hyrocarbon groups bound to poly(ethylene glycol), deltalog K, where K is the partition coefficient, is taken as a measure of hydrophobic interaction. Deltalog K varies with size of hydrocarbon chain and type of protein. The length of the aliphatic chain should be greater than 8 carbon atoms in order to get a measurable effect in terms of deltalog K. Bovine serum albumin, beta-lactoglobulin, hemoglobin and myoglobin have been shown to have different affinities for palmitic acid ester of poly(ethylene glycol). No hydrophobic effect could be observed for ovalbumin, cytochrome c or alpha-chymotrypsinogen A.


Subject(s)
Fatty Acids , Polyethylene Glycols , Proteins/isolation & purification , Binding Sites , Chemical Phenomena , Chemistry, Physical , Hydrogen-Ion Concentration , Mathematics , Molecular Weight , Protein Binding
SELECTION OF CITATIONS
SEARCH DETAIL
...